ARCHIVES

Cell Therapeutics To Appeal FDA Decision on Pixantrone.

This article is from The Cancer Letter archive.

Vol. 36 No. 33 | September 17, 2010

Download PDF Visit The Full Archive

Related Articles

With $1.1 Billion At Stake, Cancer Groups Mull Comparative Effectiveness Studies

May 22, 2009

NIH appoints panel to review conflict of interest rules.

February 27, 2004

FDA Advisors Recommend Approval Of Topotecan for Ovarian Cancer

April 26, 1996

HHS Agency Says It Has No Jurisdiction And No Cause to Act on I-ELCAP Allegations

March 2, 2012

Screening Guidelines Differ Among Major Medical Organizations

January 16, 1998

NCAB Committee, SORDS Agree On New Training Grants In Surgical Oncology

January 11, 1985